Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenene Thomas - Investor Relations Walter Klemp - Chairman and Chief Executive Officer John Paul Waymack - Senior Chief Medical Officer Jonathan Foster - Executive Vice President and Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Jeff Jones - Oppenheimer Operator Hello and welcome to the Moleculin Biotech Q1 2023 Quarterly Update Conference Call and Webcast. [ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37758 MOLECULIN BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-4671997 (State or ...

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2022 Earnings Conference Call March 23, 2023 8:30 AM ET Company Participants Jenene Thomas - Investor Relations Walter Klemp - Chairman and Chief Executive Officer John Paul Waymack - Senior Chief Medical Officer Jonathan Foster - Executive Vice President and Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Jeff Jones - Oppenheimer Operator Hello and welcome to the Moleculin Biotech Fiscal Year 2022 Quarterly Update Conference Call and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the transition period from to Commission File Number: 001-37758 Moleculin Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-4671997 (State or Other Juri ...

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Walter Klemp – Chairman and Chief Executive Officer Jonathan Foster – Executive Vice President and Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH Capital Operator Hello, and welcome to the Moleculin Biotech Inaugural Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions] ...

Better Treatments, More Tomorrows INVESTOR PRESENTATION / FEBRUARY 15, 2022 MOLECULIN.COM / NASDAQ: MBRX Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are inten ...

Better Treatments, More Tomorrows INVESTOR PRESENTATION / MAY 2021 MOLECULIN.COM / NASDAQ: MBRX DISCLAIMER 2 All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to ...

Moleculin Developing ground-breaking therapies for highly resistant cancers and viruses March 8, 2021 March Investor Public Presentation (Nasdaq: MBRX) Disclaimer 2 All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "int ...

Moleculin Developing ground-breaking therapies for highly resistant cancers and viruses September 1, 2020 Public Presentation (Nasdaq: MBRX) Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect ...